LC-MS/MS is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ in preclinical models |
| Molecular formula | C20H24ClN3O4S | Reported for the parent compound |
| CAS Registry Number | 1379686-30-2 | Common identifier in chemical databases |
| Appearance | Off-white to pale yellow solid | Typical research chemical solid |
| Solubility | Soluble in DMSO and ethanol; low in water | Class: small organic molecule |
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
== Procedure == This section covers livestock Cryo-branding. Since the 1960s, experimental work has been carried out on freeze brands for other animals. Around seventy species have been evaluated to date. These efforts are summarized in Freeze brand § Table of branding durations.
Upon taking office in 2019, Newsom succeeded Brown as co-chair of the United States Climate Alliance. In September 2019, Newsom vetoed SB 1, which would have preserved environmental protections at the state level that were set to roll back nationally under the Trump administration's environmental policy. In February 2020, the Newsom administration sued federal agencies over the rollbacks to protect imperiled fish in the Sacramento–San Joaquin River Delta in 2019. Newsom attended the 2019 UN Climate Action Summit, where he spoke of California as a climate leader due to the actions of governors before him. In August 2020, he addressed the 2020 Democratic National Convention. His speech mentioned climate change and the wildfires prevalent in California at the time. On September 23, 2020, Newsom signed an executive order to phase out sales of gasoline-powered vehicles and require all new passenger vehicles sold in the state to be zero-emission by 2035. Bills he signed in September with an environmental focus included a commission to study lithium extraction around the Salton Sea. During his 2018 campaign, Newsom pledged to tighten state oversight of fracking and oil extraction. Early in his governorship, his administration approved new oil and gas leases on public lands at about twice the rate of the prior year. When asked about this development, Newsom said he was unaware of the rate of approvals, and he later fired the head of the Division of Oil, Gas and Geothermal Resources.
=== PIP1 and PIP2 === The 3-D structures of the open and closed forms of plant aquaporins, PIP1 and PIP2, have been solved (PDB: 4JC6). In the closed conformation, loop D caps the channel from the cytoplasm and thereby occludes the pore. In the open conformation, loop D is displaced up to 16 Å, and this movement opens a hydrophobic gate blocking the channel entrance from the cytoplasm. These results reveal a molecular gating mechanism which appears conserved throughout all plant plasma membrane aquaporins. In plants it regulates water intake/export in response to water availability and cytoplasmic pH during anoxia.
Using a long capillary tube, and including potassium chloride aerosols in the helium gas, the mendelevium atoms can be transported over tens of meters to be chemically analysed and have their quantity determined. The mendelevium can then be separated from the foil material and other fission products by applying acid to the foil and then coprecipitating the mendelevium with lanthanum fluoride, then using a cation-exchange resin column with a 10% ethanol solution saturated with hydrochloric acid, acting as an eluant. However, if the foil is made of gold and thin enough, it is enough to simply dissolve the gold in aqua regia before separating the trivalent actinides from the gold using anion-exchange chromatography, the eluant being 6 M hydrochloric acid. Mendelevium can finally be separated from the other trivalent actinides using selective elution from a cation-exchange resin column, the eluant being ammonia α-HIB.< Using the gas-jet method often renders the first two steps unnecessary. Another possible way to separate the trivalent actinides is via solvent extraction chromatography using bis-(2-ethylhexyl) phosphoric acid (abbreviated as HDEHP) as the stationary organic phase and nitric acid as the mobile aqueous phase. The actinide elution sequence is reversed from that of the cation-exchange resin column, so that the heavier actinides elute later.
Sources: en.wikipedia.org
Recent theoretical developments in noble gas chemistry, in which helium is expected to show slightly less inertness than neon and to form (HeO)(LiF)2 with a structure similar to the analogous beryllium compound (but with no expected neon analogue), have resulted in more chemists advocating a placement of helium in group 2. This relates to the electronic argument, as the reason for neon's greater inertness is repulsion from its filled p-shell that helium lacks, though realistically it is unlikely that helium-containing molecules will be stable outside extreme low-temperature conditions (around 10 K). The first-row anomaly in the periodic table has additionally been cited to support moving helium to group 2. It arises because the first orbital of any type is unusually small, since unlike its higher analogues, it does not experience interelectronic repulsion from a smaller orbital of the same type. This makes the first row of elements in each block have unusually small atoms, and such elements tend to exhibit characteristic kinds of anomalies for their group. Some chemists arguing for the repositioning of helium have pointed out that helium exhibits similar anomalies if it is placed in group 2, but not if it is placed in group 18: on the other hand, neon, which would be the first group 18 element if helium was removed from that spot, does exhibit similar anomalies. The relationship between helium and beryllium is then argued to resemble that between hydrogen and lithium, a placement which is much more commonly accepted.
MSC-1 measured the electrostatic charge in the spacecraft. MSC-2 was a proton-electron spectrometer. MSC-3 was a tri-axis magnetometer. MSC-10 involved the crew photographing the red-blue Earth limb. Photographs were taken over the Middle East and the southwestern United States; several air fields indicated on charts were identified. The crew had 16 freeze-dried meals and ate all but one of them. As they lacked any means of measuring water intake, they attempted to minimize consumption of it and also reported high amounts of gas bubbles in the water from the water dispenser. They experienced a degree of eye, nose, and throat irritation early in the flight and post-landing. This was attributed to ammonia fumes from the flame retardant used in the cabin, which was changed to a different material on subsequent flights.
=== Insulin secretion === The glucose that goes into the bloodstream after food consumption also enters the beta cells in the islets of Langerhans in the pancreas. The glucose diffuses in the beta-cell facilitated by a GLUT-2 vesicle. Inside the beta cell, the following process occurs: Glucose gets converted to glucose-6-phosphate (G6P) through glucokinase, and G6P is subsequently oxidized to form ATP. This process inhibits the ATP-sensitive potassium ion channels of the cell causing the potassium ion channel to close and not function anymore. The closure of the ATP-sensitive potassium channels causes depolarization of the cell membrane causing the cell membrane to stretch which causes the voltage-gated calcium channel on the membrane to open causing an influx of Ca2+ ions. This influx then stimulates fusion of the insulin vesicles to the cell membrane and secretion of insulin in the extracellular fluid outside the beta cell; thus making it enter the bloodstream. [Also Illustrated in Figure 1.1.1]. There are 3 subfamilies of Ca2+ channels; L-type Ca2+ channels, non-L-type Ca2+ channels (including R-type) and the T-type Ca2+ channels. There are two phases of the insulin secretion, the first phase involves the L-type Ca2+ channels and the second phase involves the R-type Ca2+ channels. The Ca2+ influx generated by R-type Ca2+ channels is not enough to cause insulin exocytosis, however, it increases the mobilization of the vesicles towards the cell membrane.
Sources: en.wikipedia.org
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.
No. It is a synthetic ligand that binds nuclear receptors, not a steroid or peptide hormone. Its activity depends on receptor binding rather than endocrine secretion.
Clinical evidence is limited. Most published data come from cell and animal experiments. Human safety and efficacy remain uncertain.
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.